NCT00569985View on ClinicalTrials.gov

Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

November 12, 2019

Study Completion Date

November 12, 2019

Conditions
Lymphoma
Interventions
BIOLOGICAL

lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells

Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells

DRUG

carmustine

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

etoposide

Given IV

PROCEDURE

autologous hematopoietic stem cell transplantation

Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells

Trial Locations (1)

91010-3000

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00569985 - Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma | Biotech Hunter | Biotech Hunter